ITHACA, NY – Kanvas Biosciences, a pioneering biotechnology research company based in Ithaca, NY, is thrilled to announce the successful completion of its pre-Series A funding round, raising an impressive $12 million. The funding round was led by prominent venture capital firm DCVC, with participation from Uncommon Denominator and Triple Impact Capital.

Kanvas Biosciences aims to revolutionize the field of microbiology by developing innovative tools and methodologies for imaging microbes and analyzing their surrounding environments. With a mission to unravel the mysteries of microbial life, the company is poised to make groundbreaking contributions to the biotechnology industry.

Speaking about the funding, Matthew Cheng, the Founder of Kanvas Biosciences, expressed his gratitude to the investors and highlighted the significance of this milestone. "We are thrilled to have the support of DCVC, Uncommon Denominator, and Triple Impact Capital as we embark on our journey to transform the way we understand and harness the power of microbes," said Cheng. "This funding will propel us forward in our quest to develop cutting-edge tools that will shape the future of biotechnology research."